

Peter S Hendricks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12014579/publications.pdf>

Version: 2024-02-01

66
papers

2,777
citations

218677

26
h-index

214800

47
g-index

66
all docs

66
docs citations

66
times ranked

2777
citing authors

#	ARTICLE	IF	CITATIONS
1	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. , 2019, 197, 83-102.		296
2	Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology, 2015, 29, 280-288.	4.0	278
3	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 2018, 142, 143-166.	4.1	184
4	The early time course of smoking withdrawal effects. Psychopharmacology, 2006, 187, 385-396.	3.1	179
5	Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis. Addiction, 2020, 115, 201-217.	3.3	162
6	How Low Should You Go? Determining the Optimal Cutoff for Exhaled Carbon Monoxide to Confirm Smoking Abstinence When Using Cotinine as Reference. Nicotine and Tobacco Research, 2014, 16, 1348-1355.	2.6	122
7	Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry, 2018, 30, 331-342.	2.8	98
8	Pairing smoking cessation services with lung cancer screening: A clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco. Cancer, 2016, 122, 1150-1159.	4.1	97
9	The increasing recalcitrance of smokers in clinical trials II: Pharmacotherapy trials. Nicotine and Tobacco Research, 2003, 5, 27-35.	2.6	90
10	Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Journal of Psychopharmacology, 2014, 28, 62-66.	4.0	65
11	Psilocybin, psychological distress, and suicidality. Journal of Psychopharmacology, 2015, 29, 1041-1043.	4.0	62
12	The relationships of classic psychedelic use with criminal behavior in the United States adult population. Journal of Psychopharmacology, 2018, 32, 37-48.	4.0	61
13	Mechanisms of change in extended cognitive behavioral treatment for tobacco dependence†. Drug and Alcohol Dependence, 2010, 109, 114-119.	3.2	53
14	Smoking abstinence-related expectancies among American Indians, African Americans, and women: Potential mechanisms of tobacco-related disparities.. Psychology of Addictive Behaviors, 2014, 28, 193-205.	2.1	51
15	A measure of perceived pain and tobacco smoking interrelations: pilot validation of the pain and smoking inventory. Cognitive Behaviour Therapy, 2017, 46, 339-351.	3.5	50
16	Electronic cigarettes and nicotine dependence: evolving products, evolving problems. BMC Medicine, 2015, 13, 119.	5.5	47
17	Electronic cigarettes in adults in outpatient substance use treatment: Awareness, perceptions, use, and reasons for use. American Journal on Addictions, 2015, 24, 233-239.	1.4	46
18	Hallucinogen use and intimate partner violence: Prospective evidence consistent with protective effects among men with histories of problematic substance use. Journal of Psychopharmacology, 2016, 30, 601-607.	4.0	46

#	ARTICLE	IF	CITATIONS
19	The Smoking Abstinence Questionnaire: measurement of smokers' abstinence-related expectancies. <i>Addiction</i> , 2011, 106, 716-728.	3.3	43
20	Associations between lifetime classic psychedelic use and markers of physical health. <i>Journal of Psychopharmacology</i> , 2021, 35, 447-452.	4.0	41
21	Expectancy priming of smoking cessation messages enhances the placebo effect of tailored interventions.. <i>Health Psychology</i> , 2007, 26, 598-609.	1.6	39
22	Hospitalized smokers' expectancies for electronic cigarettes versus tobacco cigarettes. <i>Addictive Behaviors</i> , 2015, 41, 106-111.	3.0	38
23	Abstinence-related expectancies predict smoking withdrawal effects: implications for possible causal mechanisms. <i>Psychopharmacology</i> , 2013, 230, 363-373.	3.1	36
24	Evaluating the validities of different DSM-IV-based conceptual constructs of tobacco dependence. <i>Addiction</i> , 2008, 103, 1215-1223.	3.3	33
25	Electronic Cigarette Awareness, Use History, and Expected Future Use Among Hospitalized Cigarette Smokers. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1512-1517.	2.6	33
26	Race and Medication Adherence Moderate Cessation Outcomes in Criminal Justice Smokers. <i>American Journal of Preventive Medicine</i> , 2015, 49, 335-344.	3.0	33
27	Alcohol and Marijuana Use in the Context of Tobacco Dependence Treatment: Impact on Outcome and Mediation of Effect. <i>Nicotine and Tobacco Research</i> , 2012, 14, 942-951.	2.6	30
28	Randomised controlled trial of stand-alone tailored emails for smoking cessation. <i>Tobacco Control</i> , 2018, 27, 136-146.	3.2	29
29	Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics. <i>Frontiers in Psychiatry</i> , 2019, 10, 896.	2.6	28
30	Smoking expectancy associates among college smokers. <i>Addictive Behaviors</i> , 2005, 30, 235-245.	3.0	26
31	Mixed-amphetamine salts expectancies among college students: Is stimulant induced cognitive enhancement a placebo effect?. <i>Drug and Alcohol Dependence</i> , 2017, 178, 302-309.	3.2	26
32	Associations between lifetime classic psychedelic use and cardiometabolic diseases. <i>Scientific Reports</i> , 2021, 11, 14427.	3.3	24
33	Prevalence and epidemiological associates of novel psychedelic use in the United States adult population. <i>Journal of Psychopharmacology</i> , 2019, 33, 1058-1067.	4.0	23
34	The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 344-350.	1.7	22
35	Gender, Ethnicity, and Their Intersectionality in the Prediction of Smoking Outcome Expectancies in Regular Cigarette Smokers. <i>Behavior Modification</i> , 2016, 40, 281-302.	1.6	21
36	Longitudinal and Reciprocal Relationships Between Psychological Well-Being and Smoking. <i>Nicotine and Tobacco Research</i> , 2020, 22, 18-23.	2.6	21

#	ARTICLE	IF	CITATIONS
37	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. <i>International Journal of Drug Policy</i> , 2021, 98, 103380.	3.3	21
38	Smokers'™ expectancies for abstinence: Preliminary results from focus groups.. <i>Psychology of Addictive Behaviors</i> , 2009, 23, 380-385.	2.1	20
39	Clinical Significance of Early Smoking Withdrawal Effects and Their Relationships With Nicotine Metabolism: Preliminary Results From a Pilot Study. <i>Nicotine and Tobacco Research</i> , 2014, 16, 615-620.	2.6	19
40	Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year. <i>Hypertension</i> , 2021, 77, 1510-1516.	2.7	17
41	A pilot trial of In vivo NRT sampling to increase medication adherence in community corrections smokers. <i>Addictive Behaviors</i> , 2017, 67, 92-99.	3.0	13
42	Expectancies for the Effectiveness of Different Tobacco Interventions Account for Racial and Gender Differences in Motivation to Quit and Abstinence Self-Efficacy. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1174-1182.	2.6	12
43	Mental Health and the Association between Asthma and E-cigarette Use among Young Adults in The United States: A Mediation Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8799.	2.6	12
44	Smokers' expectancies for smoking versus nicotine.. <i>Psychology of Addictive Behaviors</i> , 2008, 22, 135-140.	2.1	11
45	Expectancies for smoking cessation among drug-involved smokers: Implications for clinical practice. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 320-324.	2.8	11
46	An integration of cognitive-behavioral therapy and interpersonal psychotherapy for bulimia nervosa: A case study using the case formulation method. <i>International Journal of Eating Disorders</i> , 2005, 37, 171-174.	4.0	10
47	Back to the future: A return to psychedelic treatment models for addiction. <i>Journal of Psychopharmacology</i> , 2014, 28, 981-982.	4.0	10
48	Psilocybin and palliative end-of-life care. <i>Journal of Psychopharmacology</i> , 2016, 30, 1207-1208.	4.0	10
49	Withdrawal exposure with withdrawal regulation training for smoking cessation: a randomized controlled pilot trial. <i>Drug and Alcohol Dependence</i> , 2016, 164, 28-37.	3.2	8
50	Mental health disorders and alcohol use are associated with increased likelihood of smoking relapse among people living with HIV attending routine clinical care. <i>BMC Public Health</i> , 2019, 19, 1409.	2.9	8
51	If at first you don't succeed: Characterization of smokers with late smoking abstinence onset. <i>Addictive Behaviors</i> , 2015, 45, 34-38.	3.0	7
52	Predictors of medication adherence and smoking cessation among smokers under community corrections supervision. <i>Addictive Behaviors</i> , 2017, 65, 111-117.	3.0	7
53	Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations. <i>Neuropharmacology</i> , 2022, 214, 109127.	4.1	7
54	Self-reported reductions in tobacco and nicotine use following medical cannabis initiation: Results from a cross-sectional survey of authorized medical cannabis patients in Canada. <i>Journal of Substance Abuse Treatment</i> , 2021, 130, 108481.	2.8	6

#	ARTICLE	IF	CITATIONS
55	The Relationships of Expectancies With E-cigarette Use Among Hospitalized Smokers: A Prospective Longitudinal Study. <i>Nicotine and Tobacco Research</i> , 2018, 20, 224-230.	2.6	5
56	Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study. <i>Journal of Psychopharmacology</i> , 2022, 36, 337-347.	4.0	5
57	Lack of utility of cigarettes per day cutoffs for clinical and laboratory smoking research. <i>Addictive Behaviors</i> , 2019, 98, 106066.	3.0	4
58	Classic psychedelics as therapeutics for psychiatric disorders. <i>Handbook of Behavioral Neuroscience</i> , 2020, 31, 959-966.	0.7	4
59	Varenicline for Smoking Reduction Prior to Cessation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2284.	7.4	3
60	Predictors of smoking cessation among people living with HIV receiving routine clinical care. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2019, 31, 1353-1361.	1.2	3
61	Psilocybin-assisted group therapy: A new hope for demoralization. <i>EClinicalMedicine</i> , 2020, 27, 100557.	7.1	3
62	A Pilot Study of Nicotine Replacement Therapy Sampling and Selection to Increase Medication Adherence in Low-Income Smokers. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1575-1583.	2.6	3
63	Shedding Light on Classic Psychedelics and Self-Harm. <i>Journal of Clinical Psychiatry</i> , 2022, 83, .	2.2	3
64	Electronic Cigarette Awareness, Use, and Perceptions among Cancer Patients. <i>OTO Open</i> , 2018, 2, 2473974X1877454.	1.4	1
65	Racial disparities and factors associated with prescription for smoking cessation medications among smokers receiving routine clinical care for HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2020, 32, 1207-1216.	1.2	1
66	Classic Psychedelics and Rational Suicide in the Elderly: Exploring the Potential Utility of a Reemerging Treatment Paradigm. , 2017, , 203-210.		0